ANOVA Stem Cell based Treatment for Parkinson’s Disease
Parkinson’s Disease (PD) affects millions of people worldwide. The disease is characterized by a slow and progressive deterioration of nerve cells (neurons). It is caused by the death of dopamine-producing neurons in the brain. All currently available medications for Parkinson's are limited to medicating the symptoms only.
Stem cell therapies have demonstrated the ability to stimulate repair and regenerate damaged neurons. ANOVA's Stem Cell Secretome Therapy is the latest development from current stem cell research, allowing for an exciting new treatment option that offers minimal risk and immense potential to slow down the disease's progression at different stages.
Parkinson's Diesease: A chronic neurodegenerative disease that is handled with symptom-masking medications only
Parkinson’s Disease is a chronic neurodegenerative disorder caused by selective and gradual loss of dopamine-producing neurons. These neurons are spread throughout the brain, however, the most effected region is the “substantia nigra”. The symptoms of Parkinson's Disease are mainly tremor and rigor. At later stages the illness is characterized by more severe symptoms like speech disorder, depression or even dementia.
Currently, there is no cure for Parkinson’s disease.
Nevertheless, there are few hormone replacement-based therapies which tackle the symptoms only. These pharmacological treatments are effective to control the symptoms of PD to a certain degree, with side effects, but are unable to stop neural degeneration, let alone replace dead dopaminergic cells.
Parkinson’s Disease Therapy with Stem Cells:
How can Stem Cells help?
Diverse stem cell types are under scientific investigations, some of which are in clinical trials, for the safety and efficacy of stem cell-based therapies for treating Parkinson’s disease. They include:
- Dopamine-producing Embryonic Stem Cells (ESCs) for Parkinson’s disease
- Induced pluripotent stem cells (i.e. iPS or iPSCs) for Parkinson’s disease
- Neural stem cells for Parkinson’s disease
- Bone Marrow Concentrate (BMC) for Parkinson’s disease
- Stromal Vascular Fraction (SVF) for Parkinson’s disease
- Lab-grown Mesenchymal Stem Cells (MSCs) for Parkinson’s disease
Modern stem cell research conducted with animals, mainly rats and mice, provided encouraging results in treating PD, bringing regenerative medicine a step closer to finding the cure. Looking at the science of therapies that are based on BMC, SVF and MSCs, in more detail, showed that they were not able to exert their regenerative effects in stimulating the birth of millions of new functioning neurons, from the limited stem cell pool found in the body. Ideally, this is what one could hope for, in order to cure PD.
Nevertheless, some stem cells appear to be able to migrate into the brain and unfold their positive effects, which is a promising fact towards finding an effective treatment for PD. These cells are recruited via paracrine signalling by extracellular vesicles (messaging products) that stem cells secrete and use to communicate with their surroundings. Consequently, the production of neurotrophic (stimulating growth of nervous tissue) factors is also induced. The so-called Stem Cell Secretome mainly consists of extracellular vesicles (exosomes, microvesicles, growth factors, etc.) that possess the regenerative powers of stem cells.
ANOVA is actively following the outcomes of current scientific literature and discoveries to offer the most promising and safest experimental stem cell therapy for Parkinson’s disease available today.
Stem cell research for Parkinson’s Disease:
What can we do today?
The ANOVA Stem Cell Secretome Therapy for Parkinson ’s disease uses Mesenchymal Stem Cells (MSCs) for the treatment of other conditions as well. Human trials of MSCs in PD patients have so far shown encouraging results.
MSCs have been shown to secrete many trophic (e.g. prostaglandin E2, TGF-β1, HGF, SDF-1α, indoleamine-2,3-dioxygenase, IL-4, IL-6 and IL-10, SCF, LIF, FGF-2, VEGF, IL-6, EGF, VEGF, Neurotrophin-3 (NT3), SDF-1α, and BDNF), and neuroprotective factors (e.g. NGF, GDNF and BDNF).
The microRNAs (miR-29a, miR-9, miR-124, miR-145) secreted from MSCs' exosomes were also found to promote the differentiation of stem cells into neural cells. In addition to this broad spectrum of neurotrophic and repair inducing factors, exposure of neurons and astrocytes to MSC extracted exosomes leads to an increase of miR-133b. This process promotes the functional recovery of neurons in PD and Spinal Cord Injury.
ANOVA's Stem Cell Secretome is an uniquely designed method, produced specifically to harness and highly concentrate the essence of these bioactive factors, for your personalized treatment. The Secretome, likewise, is produced in full accordance with state of the art methods and German quality controls to ensure the highest quality and safety for our patients.
We are convinced by data that our method is a promising, effective and much safer treatment than injection of MSCs solely. One of the most important factors of why our method is safe is due to the fact that it relies on growing autologous (from the same patient) fat-derived mesenchymal stem cells (MSC) in a sterile laboratory setting.
New therapeutic approaches that are not solely based on symptomatic reduction, such as the increase of the autophagy process by kinase inhibitors (that are currently undergoing clinical trials) are considered at ANOVA. They can be included when we design the treatment plan of each individual patient.
If you have any questions, with regards to our stem cell-based treatments and Parkinson's disease or the cost of treatment, then please feel free to contact us by clicking here.
Frequently Asked Questions for Stem Cell treatment of Parkinson's disease
Currently not. In the near future this is much more likely to happen. However, stem cells already hold huge potential for treating most neurodegenerative diseases, especially Parkinson’s Disease, to slow down or prevent the progression of the disease. This makes it worthwhile for every PD patient to consider trying stem cell-based therapies, to see whether it would yield them a benefit in the long run. More often than not they do benefit the patient. However, for these advanced therapeutics that are acting on a transmitter and paracrine (inter-cell communication) level, the individual success is currently not possible to be predicted without trying. We recommend that you contact us to get an expert opinion on your case and the possibilities we can offer..
The treatment of Parkinson’s disease with any stem cell method is independent of the stage. Stem cells secrete many healing factors, which induce a “flourishing” effect on local resident (stem) cells, as well as anti-inflammatory effects wherever they are deployed. This has very positive effects on PD at all stages. However, anticipated results may vary are depending on the progression the treatment plan and the side medications. Contact us for a consultation.
New treatments are generally not widely accepted, taught or even mentioned in medical text books or training events. So the odds are that most doctors never heard of them until sufficient scientific evidence has been accumulated and a solid financial support has been able to push them publicly on the market. Industries like the pharmaceutical industry have become incredibly efficient in that process, but for smaller groups, such funding is limited. Yet we at ANOVA are investing in what we can to push the scientific progress further, to offer this treatment option to our patients.
As with any personalized medical treatment, effects of each therapy can vary from patient to patient. In general, we expect positive effects or at least a slowing down of the progression after a few applications with stem cell-based therapies. Please get in touch with us for more information.
The underlying cause for the death of nerve cells in the brain are unknown. Several factors are known to play a role:
• Genes: Specific gene mutations were shown to increase the risk for PD
• Environment: Exposure to certain toxins may increase PD risk.
• Age: Usually the age of 60 is the age where PD is most prone to happen
• Sex: Men are more likely to develop PD
Occurring changes in PD changes may be related to Lewy bodies and the Alpha-Synuclein (SNCA) that is contained within these Lewy bodies
Early symptoms and possible warning signs of Parkinson’s disease (PD) are:
• Writing becomes difficult and font is getting involuntarily smaller
• One sided tremor or shaking
• Involuntarily index finger and thumb rolling
• Dizziness or fainting
• Change of facial expression known as mask face
• Soft or lower voice then usual
• Sleep problems usually accompanied with sudden movements
• Walking and otherwise subconscious movements only seem possible when actively imitating them
• Hunching over or stooping
Early symptoms of Parkinson’s disease often go unnoticed. Often one-sided symptoms are first to give indications, as listed below. When noted, a proper diagnose by neurologist needs to be made, as all symptoms can have other causes too:
- Writing changes towards the end of words and sentences
- Balance and posture problems
- Tremor usually starting with the hand at rest or in the thumb and forefingers rolling against each other
- Slowed movements
- Rigid and stiff muscles
- Speech changes
- Decreased ability to do unconscious movements
Parkinson Stage 1: Only mild symptoms occur in facial expressions or slight tremor. However, the daily life is only minimally affected and only one sided.
Parkinson Stage 2: At this stage symptoms are getting worse and affect both sides. The tremor and waling problems are getting worse. Often this is the stage where L-Dopamine is employed.
Parkinson Stage 3: Loss of balance and slowed movements characterize this stage. Living independently is still possible but symptoms significantly impair daily activities.
Parkinson Stage 4: The Symptoms are severely limiting every activity, especially walking. Movements are still possible but may require aid. Usually living alone is not possible at this stage any more.
Parkinson Stage 5: The final and most debilitating stage, where stiffness in legs makes movement impossible. The person requires full time nursing and is bound to the wheelchair. Usually many non-motoric symptoms set like delusions, hallucinations and depressions.
The disease itself is not fatal. However, related complications and symptoms can reduce the life expectancy secondarily. A study from the UK found that the life expectancy is between 3-5 years shorter than the average, when the onset of PD is at an age of 65 or older.
Yes, they are an option. Depending on health factors, it is definitely worth trying to make a high dose Stem Cell based treatment possible. The Stem Cell Secretome therapy would be an ideal treatment option for PD, as the dose can be designed. The secretome therapy can be combined with other new experimental treatments, as well. We recommend that you contact us to get an expert opinion on this subject.
- Riecke J. et al. "A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease." Stem cells and development 24.18 (2015): 2082-2090.
- Ahmed HH. et al. "Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells." World journal of stem cells 8.3 (2016): 106.
- Equbal Z. and Mukhopadhyay A. "Counting on Mesenchymal Stem Cells: A Hope for Treating Parkinson’s Disease. J Stem Cells Res." Rev & Rep 3.1 (2016): 1022.
- Wei X. et al. "Mesenchymal stem cells: a new trend for cell therapy." Acta Pharmacologica Sinica 34.6 (2013): 747-754.
- Wang S. et al. "Clinical applications of mesenchymal stem cells." Journal of hematology & oncology 5.1 (2012): 19.
- Gu W. et al. "Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord." Neuropathology 30.3 (2010): 205-217.
- Wilkins A. et al. "Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro." Stem cell research 3.1 (2009): 63-70.